Merck & Co., Inc. (NYSE:MRK) Shares Sold by P.A.W. Capital Corp

P.A.W. Capital Corp trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 13.0% during the second quarter, Holdings Channel reports. The firm owned 10,000 shares of the company’s stock after selling 1,500 shares during the quarter. Merck & Co., Inc. comprises 1.3% of P.A.W. Capital Corp’s portfolio, making the stock its 19th largest holding. P.A.W. Capital Corp’s holdings in Merck & Co., Inc. were worth $912,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Landmark Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the 1st quarter worth about $25,000. Joseph P. Lucia & Associates LLC acquired a new position in Merck & Co., Inc. during the 1st quarter valued at about $25,000. Front Row Advisors LLC increased its stake in Merck & Co., Inc. by 89.4% during the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after buying an additional 160 shares during the period. Okabena Investment Services Inc. acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $27,000. Finally, Western Pacific Wealth Management LP acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $29,000. 73.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRK has been the topic of several research analyst reports. Cowen raised their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research note on Monday, June 27th. Cowen raised their target price on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research note on Monday, June 27th. SVB Leerink raised their target price on shares of Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research note on Monday, September 12th. UBS Group raised their price objective on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the company a “neutral” rating in a research report on Monday, July 18th. Finally, Morgan Stanley raised their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $98.28.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $84.53 on Thursday. The company has a 50 day simple moving average of $88.96 and a 200-day simple moving average of $87.74. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15. The firm has a market capitalization of $214.14 billion, a price-to-earnings ratio of 12.94, a price-to-earnings-growth ratio of 1.16 and a beta of 0.33. Merck & Co., Inc. has a 52-week low of $71.50 and a 52-week high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.20. The business had revenue of $14.59 billion during the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The firm’s revenue was up 28.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.31 earnings per share. Equities research analysts predict that Merck & Co., Inc. will post 7.33 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be given a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a yield of 3.27%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.’s payout ratio is presently 42.27%.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.